Roivant Sciences Ltd.

Roivant said the quarter included about $200 million of R&D expense, just under $100 million of non-GAAP adjusted G&A, and $166 million of GAAP G&A expense. Cash was reported at just under $4 billion before receipt of the $772 million Moderna settlement payment, and share repurchases totaled about $200 million in the quarter, a bit more than that including March. Management reiterated that brepocitinib in dermatomyositis is expected to launch by the end of September, with the FDA PDUFA date this quarter. For PH-ILD, management said it expects a clear signal on PVR if the drug is active, while 6-minute walk is not powered and is not essential for the go/no-go decision. No revenue or EPS figures were stated in the transcript.

Matt Gline described the quarter as a “calm before the storm” and stressed that the next 6 to 12 months will be busier than the prior period. He highlighted progress on brepocitinib across multiple indications, including the start of the cutaneous sarcoidosis Phase III study, enrollment in LPP, and the upcoming DM launch if FDA approval comes through. His tone was confident but measured, repeatedly emphasizing readiness, access planning, and a “slow and steady” commercial build rather than an aggressive near-term launch curve.

No separate CFO spoke on the call; Matt Gline delivered the financial update. He said Roivant spent about $200 million on R&D in the quarter, just under $100 million of non-GAAP adjusted G&A, and $166 million of GAAP G&A, while ending with just under $4 billion of cash before the $772 million Moderna settlement payment. He also noted approximately $200 million of share repurchases in the quarter and said the company will continue repurchasing stock according to its authorizations, highlighting that recent buybacks were done at a much higher average price than earlier repurchases.

Analysts focused on the DM launch pace, PH-ILD trial readouts, and the setup for D2T RA and Graves. Management said early DM launch metrics will not be heavily disclosed right away and that the company is prioritizing physician/patient access and payer engagement; on PH-ILD, it expects a clear PVR signal but not a meaningful 6-minute walk readout because the study is not powered for that endpoint. On D2T RA, Roivant hopes to share the randomized withdrawal data, FDA discussion, and next steps together later this year, while on Graves management argued the key issue is building the market for a disease with longstanding unmet need rather than competing against a single rival.